| Methods | D: parallel C: unclear B: double WD: 1/28 J: 1‐1‐1 DU: 4‐17w/24w/‐ | |
| Participants | N: 28/27 D: 2 migraine with, 26 without aura C: Ad Hoc F: 79% A: 17‐61 years DU: 2‐45 years S: unclear, Sweden | |
| Interventions | P: 80‐160 ng C: Nadolol 40‐160 mg | |
| Outcomes | R: 8/14 vs. 5/13 F: reduction from 3.6 to 1.9 vs. 5.6 to 2.7 (sd not reported) AU: reduction from 11.5 to 4.1 vs. 17.1 to 9.2 HI: not reported AEs: 5/14 vs. 6/13 Dropouts‐AEs: 0/15 vs. 1/13 V: 0 | |
| Notes | Small, rigorous trial with relevant baseline imbalances | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.